-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly (LLY) Showcased Its Obesity Pipeline, Is It Still 3% Undervalued?

Simply Wall St·11/17/2026 20:10:02
Listen to the news

Eli Lilly (LLY) just used ObesityWeek 2026 as a showcase for its cardiometabolic pipeline, unveiling detailed data on EloraTZP, retatrutide and oral GLP-1 pill Foundayo that investors now need to weigh against today’s valuation.

ObesityWeek landed on a stock that already has momentum behind it, with Eli Lilly’s latest share price at US$1,431.67, a 30 day share price return of 13.89% and a 32.52% share price return year to date that lines up with strong interest in its incretin story. Over 12 months the total shareholder return of 40.97% and a roughly 5 year total shareholder return of 474.07% show how long term holders have been rewarded. The 16.80% 90 day share price return suggests enthusiasm has been building rather than fading as fresh data, new obesity indications, manufacturing build outs and oncology deals like Calytrix keep feeding the narrative around future cardiometabolic and cancer pipelines.

Scan the rest of the incretin trade by comparing Eli Lilly with 36 healthcare AI stocks that are building data-driven drug pipelines and cardiometabolic franchises supported by similar obesity and diabetes momentum.

Eli Lilly’s surge around ObesityWeek appears tied to concrete trial wins and factory spending, while ETF flows, short interest and a near-record share price suggest sentiment may be running hot. Which force is driving the current valuation?

Most Popular Narrative: 3% Undervalued

Compared with Eli Lilly’s last close at $1,431.67, the most followed narrative on Simply Wall St pegs fair value at $1,477.03, implying a small upside that still needs context. According to AHaron, an investor in the Simply Wall St Community who built that valuation narrative, the case leans heavily on how the obesity pipeline feeds into long term earnings power.

The model uses four inputs to arrive at the fair value. Growth rate, which has been adjusted to 18% to reflect reality rather than the overly conservative 12.71% default. A future PE ratio of 30 times earnings in 2031, down from today's 39 times, which accounts for the natural compression in valuation multiples as a company matures and grows larger. A discount rate of 7.5%, slightly above the default of 6.98%, to honestly account for the pipeline risks that still exist. And earnings by 2031 of approximately $48 to $50 billion, above the model's $41.5 billion, because at 18% growth and stable margins, that is where the numbers actually land.

See why 86 investors see Eli Lilly as 3% undervalued.

In that framework, Eli Lilly screens as modestly undervalued, with the narrative fair value of $1,477.03 sitting about 3% above the current share price. The discount rate pinned at 7.5% keeps the focus on how future cash flows from obesity and cardiometabolic drugs are being weighed against well flagged risks like pricing pressure, debt levels and heavy reliance on high margin injectables.

Result: Fair Value of $1,477.03 (UNDERVALUED)

Still, this Eli Lilly narrative leans heavily on optimistic trial outcomes and assumes that pricing pressure on obesity drugs does not erode the implied earnings power too quickly.

Find out about the key risks to this Eli Lilly narrative.

Next Steps

Sentiment around Eli Lilly is clearly split. Move quickly, review the underlying data, and weigh both sides of the story using the 3 key rewards and 2 important warning signs.

Looking for more Eli Lilly sized opportunities?

If Eli Lilly has sharpened your focus on quality, do not stop here. Use powerful stock screeners to hunt for ideas you might otherwise miss.